Synergy Pharmaceuticals, Inc. (NASDAQ: SGYPD), a developer of new drugs to treat gastrointestinal disorders and diseases, announced the pricing of an underwritten public offering of 1,875,000 units at an offering price of $8.00 per unit, with each unit consisting of two shares of common stock and one warrant to purchase one share of common stock. The units will begin trading on The Nasdaq Capital Market on December 1, 2011 under the symbol “SGYPU”. The common stock and warrants will not be separately transferable until the earlier of (i) the exercise in full of the underwriters' overallotment option or (ii) 45 days from the date of the prospectus supplement. Each warrant will have an exercise price of $5.50 per share, will be exercisable upon separation of the units and will expire five years from the date of issuance. When separately transferable, the warrants will trade on The Nasdaq Capital Market under the symbol “SGYPW”. The gross proceeds to Synergy from this offering are expected to be $15.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The offering is expected to close on December 6, 2011, subject to customary closing conditions. Synergy has also granted the underwriters a 45-day option to purchase up to an additional 281,250 units to cover over-allotments, if any. All of the units in the offering are to be sold by Synergy.
Synergy intends to use the net proceeds from this offering to fund its research and development activities, including its ongoing Phase II/III clinical trial of plecanatide and its Phase I clinical trial of SP-333, and for working capital and other general corporate purposes.
Synergy also announced that, effective as of December 1, 2011, its common stock will begin trading on The NASDAQ Capital Market under the symbol “SGYPD.” In connection with its listing on The NASDAQ Capital Market, Synergy’s common stock will cease trading on the OTC QB. Furthermore, in connection with this offering, Synergy has effected a 1-for-2 reverse stock split of its common stock which is effective for trading purposes as of December 1, 2011.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV